Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT Trialists

American Society of Clinical Oncology (ASCO) - Tập 23 Số 11 - Trang 2477-2492 - 2005
Mitch Dowsett1, Steve R. Ebbs1, J. Michael Dixon1, Anthony Skene1, Clive Griffith1, Irene Boeddinghaus1, Janine Salter1, Simone Detre1, D. Gareth Evans1, S. Ashley1, Stephen Francis1, Geraldine Walsh1, Ian E. Smith1
1From the Academic Department of Biochemistry and the Breast Unit, Royal Marsden Hospital, London; Mayday University Hospital, Croydon, Surrey; Edinburgh Breast Unit, Edinburgh; Royal Bournemouth Hospital, Bournemouth, Dorset; Royal Victoria Infirmary, Newcastle Upon Tyne, Tyne and Wear; and AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom

Tóm tắt

PurposeTo investigate the relationships between biomarker changes in breast cancer during neoadjuvant (preoperative) endocrine therapy.Patients and MethodsThe IMPACT trial compared the preoperative use of tamoxifen with anastrozole alone or in combination in postmenopausal women (n = 330) with primary breast cancer. Biomarkers were measured in tumor biopsy specimens taken at baseline, and after 2 and 12 weeks of treatment.ResultsA decrease in the proliferation marker Ki67 occurred in the majority of patients: 52 (93%) of 56, 46 (85%) of 54, and 37 (84%) of 44 patients in the anastrozole, tamoxifen, and combination groups, respectively. There was a significantly greater suppression of Ki67 in the anastrozole-treated group than in the tamoxifen- or combination-treated groups, which is parallel to the greater efficacy seen for anastrozole over these two treatments in the Arimidex, Tamoxifen, Alone or in Combination adjuvant trial. A positive relationship was noted between estrogen-receptor level and Ki67 suppression in all patients. Ki67 was reduced to a greater extent in progesterone receptor-positive tumors compared with progesterone receptor-negative tumors. HER-2-negative tumors tended to show a greater reduction in Ki67 compared with HER-2-positive tumors, but the difference was only significant in the tamoxifen group after 2 weeks, and in the anastrozole group after 12 weeks.ConclusionThese results confirm the value of Ki67 as a molecular marker, and provide information regarding the relationships between treatment-induced changes in Ki67 and other important biomarkers. Studies such as this should help integrate agents targeted at growth factor signaling with endocrine agents in breast cancer.

Từ khóa


Tài liệu tham khảo

10.1056/NEJMra023246

10.1200/JCO.2002.20.4.1026

Ellis MJ, Coop A, Singh B, et al: Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63:6523,2003-6531,

10.1200/JCO.2001.19.18.3808

Smith IE, Dowsett M: Neoadjuvant treatment of estrogen receptor-positive operable breast cancer in postmenopausal women: The IMmediate Preoperative Arimidex, tamoxifen or Combined with Tamoxifen (IMPACT) trial. J Clin Oncol 23: in press

Dowsett M, Smith IE, Ebbs SR, et al: Short term changes in Ki67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11:951s,2005-958s, (2 pt 2)

10.1016/S0140-6736(02)09088-8

10.1023/A:1013128213451

Johnston SR, Boeddinghaus IM, Riddler S, et al: Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. Cancer Res 59:3646,1999-3651,

Kyprianou N, English HF, Davidson NE, et al: Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51:162,1991-166,

10.1038/bjc.1993.111

10.1023/A:1005933815809

10.1002/cncr.11745

10.1016/S0960-0760(03)00365-0

10.1200/JCO.2003.09.099

10.1210/me.2002-0318

Dowsett M, on behalf of the ATAC Trialists' Group: Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 82:S7,2003, (abstr 5; suppl 1)

Dowsett M, Harper-Wynne C, Boeddinghaus I, et al: HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 61:8452,2001-8458,

Howell A, Harland RN, Barnes DM, et al: Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Cancer Res 47:300,1987-304,

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 23 Số 11

2477-2492

Thông tin tác giả